On November 13, 2025, Ascletis Pharma, a Hong Kong-based biopharmaceutical company specializing in innovative peptide and protein therapeutics, announced a strategic milestone in metabolic disease therapy development: the co-formulation and intended clinical advancement of ASC36—a once-monthly, next-generation amylin receptor agonist—and ASC35—a once-monthly, next-generation GLP-1/GIPR dual agonist. This development marks a significant leap in the application of peptide manufacturing, formulation science, and clinical pathway design, particularly for the Asian pharmaceutical sector, where scalable, patient-centric therapies for chronic metabolic disorders remain a high priority.

The co-formulation project is underpinned by Ascletis’s commitment to leveraging advanced peptide engineering and sustained-release delivery technologies, aiming to provide more consistent blood-level maintenance, improved patient adherence, and superior therapeutic efficacy. The significance of a once-monthly injectable format for both amylin and GLP-1/GIPR dual agonists is notable, as it has the potential to streamline the manufacturing process, reduce injection frequency, and minimize drug wastage, thus affecting supply chain optimization for pharmaceutical manufacturers, healthcare providers, and contract manufacturing organizations (CMOs) involved in large-scale peptide production and distribution.

This dual-coformulation approach holds substantial promise in the management of obesity and type 2 diabetes—disease areas projected for double-digit growth across Asian markets due to rapid urbanization, demographic shifts, and changing lifestyle patterns. The company outlined that both drug candidates have been optimized for high peptide stability and compatibility, enabling efficient co-lyophilization, improved shelf stability, and simplified cold chain logistics management. These advancements directly address traditional peptide formulation challenges, including peptide aggregation, unstable pharmacokinetics, and temperature-sensitive shipment, thereby reducing costs and compliance risks for regional logistics and manufacturing operations.

Business executives and R&D leaders noted that Ascletis is pursuing this innovation through a rigorous regional regulatory pathway, preparing for pivotal clinical trials scheduled to commence in 2026. The company’s technology platform integrates process analytics, bioprocess automation, and in-process quality controls, in line with evolving Asian GMP regulations that prioritize data integrity, batch traceability, and digitalized process monitoring. These technological upgrades are expected to set a new benchmark for biopharmaceutical manufacturing excellence, with implications for both internal operations and outsourcing partnerships, especially with local and regional CMOs.

Supply chain and procurement professionals were briefed that the co-formulation could simplify distribution networks, reduce cold storage requirements, and create new synergies for pharmaceutical wholesalers. The single-vial, once-monthly format is designed to reduce inventory financing burdens and improve shelf management for institutional buyers—benefits echoed by global CROs and distribution partners operating in high-growth Asian markets. In addition, the approach is expected to enhance patient access and reduce direct care provider workloads, which are key metrics in payer negotiations and health technology assessment (HTA) submissions increasingly required by government and private payors in Asia.

Ascletis plans to host a dedicated conference call in Mandarin on November 13, 2025, to provide further details to institutional investors, manufacturing partners, and the broader pharma business analyst community, focusing on technology transfer, intellectual property strategy, and regulatory coordination across key Asian markets. The unveiling of this co-formulation initiative positions Ascletis as a leader in both technical innovation and market-focused execution, setting a new trajectory for the regional manufacturing and clinical landscape for peptide-based therapies.